全身性抗真菌薬

Abstract

Overview

Introduction

The market for antifungals is shifting. Sales of old market leade, Pfizer' s diflucan, have been eroded by generics, and a clear new market leader has yet to emerge. Relatively new drugs within the azole and the candin class are battling for supremacy, while entirely new approaches in the pipeline may have the potential to change the landscape yet again.

Table of Contents

• ABOUT DATAMONITOR HEALTHCARE
  • About the Infectious & Respiratory Disease pharmaceutical analysis team
• CHAPTER 1 EXECUTIVE SUMMARY
  • Objective of the analysis
  • Datamonitor insight into the systemic fungal infection market
    • Predictable, heavy losses continue but rejuvenation in sight
    • Patients, drugs, diagnostics and pathogens change market focus
    • Unmet need will require more inventive trial design to fulfil
    • Changing spectrum of clinical attractiveness
    • New blood in top ranks, but Pfizer will increase its lead
  • Contributing experts
  • Related reports
  • Upcoming related reports
• CHAPTER 2 MARKET DEFINITION AND OVERVIEW
  • Market definition for this report
  • Current market situation
    • Geographical bias
    • High market concentration of brand sales
  • Key companies, strategies and approaches
  • Disease background
    • The fungal family tree - a history of succession
      • Pathogens and patients - linking immunocompromise to species
      • From Candida to Aspergillus and beyond - changing fungal epidemiology
      • The pathogens of the future: Fusarium and Scedosporium
    • Patients - drivers of demand
      • Transplant patients - driving the need for patient and pathogen-specific drug indications
      • Cancer - a core sector for years to come
      • HIV - HAART reducing demand, but facing increased azole resistance
      • Children and neonates - a dearth of basic information
    • The antifungal drug explosion - new challenges, new opportunities
      • Amphotericin B - saving lives
      • Ketoconazole - oral opportunities
      • Fluconazole - a pharmacological revolution
      • Caspofungin - a new class and a sign of things to come
      • Lipid amphotericins - setting the pharmacoeconomic standard
    • Diagnostics - shaping new management strategies
      • Conventional technologies - still invaluable tools
      • Molecular diagnostics: changing the outlook for drug use
    • Changing treatment paradigms: towards pre-emptive and targeted therapy
      • Prophylaxis - an indication under threat
      • Pre-emptive therapy - led by diagnostic advance
      • Empiric therapy - not enough any more
      • Directed therapy - the importance of specific and costly indications
    • Current unmet need - significant, numerous, and specific
      • Mortality
      • Pediatric data
      • More specific data and indications
  • Clinical trial design
    • Dealing with limited patient populations
      • Finding other ways of growing the sample size
      • Making sure the right patients are included
    • Confounding underlying disease
      • Making sure the group is comparable
      • Avoiding mortality (in all its forms) as an endpoint
      • Reconsidering trial duration: too short, or too long?
    • Adequately measuring diagnosis and response
      • Staying with the times: get molecular
• CHAPTER 3 COUNTRY MARKET ASSESSMENTS
  • Seven major markets
    • Key facts
    • Opportunities and threats
      • Genericization of the first wave of safer drugs
      • Pharmacoeconomic analysis: influencing key decision makers
      • Which pathogen to look for next?
      • The commercial flipside: are antifungals worth it?
      • New treatment guidelines: The IDSA guidelines go international
  • United States
    • Key facts
    • Opportunities and threats
      • Broader FDA initiatives decrease time to market, but antibiotic scrutiny increases
      • DTC advertising - ideal for the acute sector, but not for antifungals
      • Pricing and reimbursement
  • Japan
    • Key facts
    • Opportunities and threats
      • The threat of foreign competition: enough to force domestic change?
      • Price cuts - still dominating pricing and reimbursement in Japan
      • Increasing uptake of generics
      • Lengthy approval process slows down access to the Japanese market
  • 5EU
    • Key facts
    • Opportunities and threats
      • EMEA drug approval process harmonization
      • Smaller companies helped by European regulators
    • France
      • Opportunities and threats
    • Germany
      • Opportunities and threats
    • Italy
      • Opportunities and threats
    • Spain
      • Opportunities and threats
    • UK
      • Opportunities and threats
• CHAPTER 4 DRUG ANALYSES AND FORECASTS
  • 7MM overview
    • Regional contributions
    • Corporate performance
      • Pfizer to remain the leader of the pack
      • Merck and Johnson and Johnson need new options
      • Astellas and Schering Plough: On the way up with simple propositions
  • Azoles
    • Key impact summary
    • Azole analysis - historical and future outlook and comparative forecasts
      • Azoles as a proportion of total market value
      • Regional variations: azole value slump limited to US
      • Class composition - currently marketed products, new and recent launches and generics
      • Textbook generic displacement
      • Generic incursion beginning to stabilize
    • Marketed product overviews
      • Diflucan (fluconazole)
      • Prodif (fosfluconazole)
      • Sporanox (itraconazole)
      • Nizoral (ketoconazole)
      • Noxafil (posaconazole)
      • Vfend (voriconazole)
    • Pipeline products
      • Isavuconazonium chloride (BAL8557)
      • Others [not forecast]
  • Echinocandins
    • Key impact summary
    • Echinocandin analysis - historical and future outlook
      • Echinocandins as a proportion of total market value
      • Class composition - new launches detract from the incumbent
      • Regional variations: Japan leads the way
      • Brand overview - a tale of two territories
    • Marketed product overviews
      • Cancidas (caspofungin)
      • Mycamine (micafungin)
      • Eraxis (anidulafungin)
    • Pipeline products [not forecast]
      • HMR-3270 (aminocandin)
  • Polyenes
    • Key impact summary
    • Polyene analysis - historical and future outlook
      • Polyenes as a proportion of total market value
      • Regional variations
      • Class composition
      • Brand overview
    • Marketed product overviews
      • Abelcet (Amphotericin B Lipid Complex)
      • AmBisome (liposomal AmB)
      • Other branded polyenes [not forecast]
    • Pipeline products
      • SinuNase & BiOral Amphotericin B (AmB Oral and Nasal cochleates)
      • NKTR-024 (amphotericin B inhalation powder)
      • Discontinued/withdrawn products
  • Others
    • Group overview
      • Others as a proportion of total market value
      • Regional sales composition
      • Branded versus generic and new launch composition
    • Pipeline products
      • Mycograb (efungumab)
      • Others [not forecast]
  • Forecast methodology
• CHAPTER 5 FORECAST ASSUMPTIONS
  • Patent expiries and generic incursion
  • Approvals and launches
  • Other studies
  • New guidelines
• BIBLIOGRAPHY
  • Presentations
  • Books
  • Journal papers
    • Epidemiology
    • Trial design and data
    • Cost efficacy
    • Diagnosis and Diagnostics
    • Presentations
  • Websites
  • Datamonitor reports
• APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
  • Summary systemic fungal disease market data
• APPENDIX B - MARKET FORECAST DATA
  • Seven major markets
  • M5EU
  • US
  • Japan
  • France
  • Germany
  • Italy
  • Spain
  • UK
• APPENDIX C
  • Contributing experts
  • Report methodology
  • About Datamonitor
    • About Datamonitor Healthcare
    • About the Infectious & Respiratory Disease analysis team
    • About the Antibacterials analysis team
    • Key therapy team members
      • Holger Rovini, Head of Respiratory and Infectious Diseases
    • Disclaimer
  • List of Tables
    • Table 1: Datamonitor product groupings for the systemic fungal infections market
    • Table 2: 7MM antifungal sales by region by volume and value (%), 2006
    • Table 3: Key players in the market for systemic fungal infection, 2007
    • Table 4: Antifungal volume sales leader board by rank, sales and share, 2006
    • Table 5: Antifungal value sales leader board by rank, sales and share, 2006
    • Table 6: Predominant and emerging opportunistic fungal pathogens of clinical significance, 2007
    • Table 7: Types of immunocompromise, causes and associated fungal pathogens
    • Table 8: Stratified risk groups for invasive Aspergillosis
    • Table 9: Examples of risk factors associated with invasive fungal infections
    • Table 10: Galactomannan testing for invasive aspergillosis in hematologic malignancy and allogeneic bone marrow transplant patients
    • Table 11: Nosocomial bloodstream infection organism distribution in the US, 2004
    • Table 12: Mortality due to invasive mycoses
    • Table 13: 7MM antifungal leading brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 14: 7MM leading antifungal brands by volume sales (SUm), 2006 and CAGR growth, 2002-06
    • Table 15: 7MM pportunities and threats in the antifungals market, 2007
    • Figure 23: Healthcare spending as a proportion of GDP in the 7MM, 2004
    • Table 16: The pharmacoeconomics of prophylaxis
    • Table 17: Definition for Immune Reconstitution Inflammatory Response in Mycoses
    • Table 18: US leading antifungal brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 19: US leading brands by volume sales (SUm), 2006 and CAGR growth, 2002-06
    • Table 20: United States: summary of opportunities and threats in the antifungals market, 2007
    • Table 21: Japan leading brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 22: Japan leading brands by volume sales 2006 (SUm) and CAGR growth, 2002-06
    • Table 23: Japan: summary of opportunities and threats in the antifungals market, 2007
    • Table 24: 5EU leading antifungal brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 25: 5EU leading antifungal brands by volume sales (SUm), 2006
    • Table 26: 5EU Opportunities and Threats in the antifungals market, 2007
    • Table 27: France leading antifungal brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 28: France leading antifungal brands by volume sales (SUm), 2006
    • Table 29: France: opportunities and threats in the antifungals market, 2007
    • Table 30: Germany leading antifungal brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 31: Germany leading antifungal brands by volume sales (SUm), 2006 and CAGR growth, 2002-06
    • Table 32: Germany: opportunities and threats in the antifungals market. 2007
    • Table 33: Italy leading antifungal brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 34: Italy leading brands by volume sales 2006 (SUm) and CAGR growth, 2002-06
    • Table 35: Italy: opportunities and threats in the antifungal market, 2007
    • Table 36: Spain leading brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 37: Spain leading brands by volume sales (SUm), 2006 and CAGR growth, 2002-06
    • Table 38: Spain: opportunities and threats in the antifungal market, 2007
    • Table 39: UK leading brands by value sales ($m), 2006 and CAGR growth, 2002-06
    • Table 40: UK leading brands by volume sales (SUm), 2006 and CAGR growth, 2002-06
    • Table 41: UK opportunities and threats in the antifungal market, 2007
    • Table 42: 7MM antifungal sales - indexed volume and value sales and average pricing, 2002-06
    • Table 43: Forecast 7MM antifungal sales by volume, value and region, 2006-2016
    • Table 44: Forecast new launches, existing products and generics by regional contribution, and CAGR (2006-16)
    • Table 45: Forecast regional sales by new launch, existing product and generic contribution, and CAGR (2006-16)
    • Table 46: Ranking and shares 2006/16 - Key players by volume and value
    • Table 47: Market growth by key player, volume and value sales, 2006-16
    • Table 48: Indexed 7MM azole class sales versus rest of antifungal market, 2002-06
    • Table 49: Forecast 7MM azole class sales versus rest of antifungal market sales, 2006-2016
    • Table 50: Indexed azole class sales by region, 2002-06
    • Table 51: Forecast azole class sales by region, 2006-2016
    • Table 52: Forecast 7MM azole sales - new launches, existing products and generics, 2006-2016
    • Table 53: Indexed 7MM azole class sales - key brands and generics, 2002-06
    • Table 54: Forecast 7MM azole class sales - key brands and generics, 2006-2016
    • Table 55: Indexed 7MM generic azole volume and value sales, 2002-06
    • Table 56: Forecast 7MM azole generic sales by molecule and combined brands, 2006-2016
    • Table 57: Diflucan: Key facts
    • Table 62: Noxafil (posaconazole) trial data overview, 2007
    • Table 69: Indexed 7MM echinocandin class sales versus rest of antifungal market by volume and value, 2002-06
    • Table 70: Forecast 7MM echinocandin class sales versus rest of antifungal market by volume and value, 2006-2016
    • Table 71: Forecast 7MM echinocandin sales - new launches, existing products and generics 2006-2016
    • Table 72: Indexed echinocandin class volume and value sales by region, 2002-06
    • Table 73: Forecast 7MM echinocandin sales by region, 2006-2016
    • Table 74: Key echinocandin brands - indexed 7MM volume and value sales, 2002-06
    • Table 75: Forecast 7MM echinocandin brand and combined generic sales, 2006-2016
    • Table 80: Indexed 7MM polyene class sales versus rest of antifungal market, 2002-06, 2002-06
    • Table 81: Forecast 7MM polyene sales versus rest of antifungal market by volume and value sales, 2006-2016
    • Table 82: Indexed 7MM polyene class sales by region, 2002-06
    • Table 83: Forecast 7MM polyene volume and value sales by region, 2006-2016
    • Table 84: Forecast 7MM polyene sales - new launches, existing products and generics, 2006-2016
    • Table 85: Indexed 7MM polyene class volume and value sales - key brands and generics, 2006
    • Table 86: Forecast 7MM volume and value polyene brand sales and combined generics, 2006-2016
    • Table 89: Other amphotericin B products
    • Table 92: Indexed 7MM other class volume and value sales versus rest of antifungal market, 2002-06,
    • Table 93: Indexed Other 7MM volume and value sales by region, , 2002-06
    • Table 94: Forecast 7MM volume and value sales of other antifungals by region, 2006-2016
    • Table 95: Indexed 7MM combined other branded products volume and value sales versus combined generic products, 2002-06
    • Table 96: Forecast 7MM volume and value Other brand sales and combined generics, 2006-2016
    • Table 98: Abelcet patent expiry, 2007-2016
    • Table 99: AmBisome patent expiry, 2007-2016
    • Table 100: Caspofungin patent expiry, 2007-2016
    • Table 101: Diflucan generic incursion, 2007-2016
    • Table 102: Eraxis patent expiry, 2007-2016
    • Table 103: Mycamine patent expiry, 2007-2016
    • Table 104: Noxafil patent expiry I, 2007-2016
    • Table 105: Vfend patent expiry I, 2007-2016
    • Table 106: BioOral (amphotericin B cochleate) Launch, 2007-2016
    • Table 107: SinuNase (amphotericin B cochleate) Launch, 2007-2016
    • Table 108: BAL8557 Launch, 2007-2016
    • Table 109: Eraxis: launch, 2007-2016
    • Table 110: Mycamine: launch, 2007-2016
    • Table 111: Mycograb: launch, 2007-2016
    • Table 112: Noxafil: Intravenous formulation launch, 2007-2016
    • Table 113: Cancidas pharmacoeconomic studies: Caspofungin versus AmB - cost-efficacy, suspected fungal infection/neutropenic fever
    • Table 114: Cancidas trials: prophylaxis, high-risk liver transplant/leukemia, 2007-2016
    • Table 115: Cancidas trials: prophylaxis/pre-emptive indications, candidiasis/aspergillosis, 2007-2016
    • Table 116: Cancidas trials: prophylaxis/pre-emptive indications, critical care indications, 2007-2016
    • Table 117: Cancidas trials: therapeutic Phase II trial data, pediatric febrile neutropenia I, 2007-2016
    • Table 118: Eraxis trial data: Anidulafungin/Voriconazole combination trial, 2007-2016
    • Table 119: Mycamine trial data: Micafungin/Voriconazole combination trial in Aspergillus, 2007-2016
    • Table 120: New IDSA Guidelines - Aspergillus, 2007
    • Table 121: New IDSA Guidelines - Blastomycosis/Sporotrichosis/Histoplasmosis, 2007
    • Table 122: New IDSA Guidelines - Candidiasis, 2007
    • Table 123: New IDSA Guidelines - Endemic mycoses, 2007
    • Table 124: New IDSA Guidelines - Prophylaxis, 2007
    • Table 125: Summary Market Data
    • Table 126: Seven major market systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 127: M5EU systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 128: US systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 129: Japan systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 130: France systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 131: Germany systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 132: Italy systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 133: Spain systemic fungal infection drug sales ($m) forecasts, 2007-16
    • Table 134: UK systemic fungal infection drug sales ($m) forecasts, 2007-16
  • List of Figures
    • Figure 1: Pharmaceutical sales by therapy area across the seven major markets ($ billion)
    • Figure 2: Indexed 7MM antifungal market sales by class, 2002-06
    • Figure 3: Performance of the US, 5EU and Japan antifungal markets, 2002-06
    • Figure 4: Key brand share of the antifungal market, 2006
    • Figure 5: Key player shares of core branded antifungal sales (%), 2006
    • Figure 6: The changing paradigms of the antifungals market, 1950s-2000s
    • Figure 7: Changing spectrum of invasive candidiasis species: episodes per 1,000 admissions, 1988-1992
    • Figure 8: Changing spectrum of invasive moulds: incidence per 1,000 patient days, 2000-03
    • Figure 9: Implications of changes in the management of underlying conditions
    • Figure 10: Milestones in organ transplant, 1950s-2000s
    • Figure 11: Timeline of fungal infection risk in solid organ transplant recipients
    • Figure 12: Availability of neonate data for fluconazole
    • Figure 13: The antifungal drug explosion - drug development since the 1950s
    • Figure 14: Cellular targets of antifungal classes
    • Figure 15: Increased hospital costs associated with Candidemia
    • Figure 16: (1-3) β-D-Glucan as a marker for invasive mycoses - cutting the time to diagnosis
    • Figure 17: Fungal infection as a continuum and therapeutic options
    • Figure 18: Questioning the value of Noxafil as an aspergillosis prophylactic
    • Figure 19: Prophylaxis, empiric and pre-emptive therapy in the context of duration of neutropenia
    • Figure 20: Unmet need in invasive fungal disease - high Candida Blood Stream Infection mortality in high-risk patient groups, 2007
    • Figure 21: Suboptimal diagnosis and outcome measurement reduces potential trial participant population in invasive aspergillosis
    • Figure 22: 7MM antifungal sales by leading brands versus rest of market by indexed value and volume sales and average price, 2002-06
    • Figure 24: Key pricing controls used globally, 2006
    • Figure 25: Net Present Value - why the antifungal pipeline differs from other infectious disease paradigms
    • Figure 26: Antifungal treatment scenarios - more creative trials with major clinical appeal
    • Figure 27: US antifungal sales by leading brands versus rest of market by indexed value and volume sales and average price, 2002-06
    • Figure 28: Decrease of FDA' s mean total approval time, 1995-2005
    • Figure 29: Generic impact of fluconazole and itraconazole patent expiries versus other generic and branded sales on the US antifungals market, 2002-06
    • Figure 30: Japanese sales by leading brands versus rest of market by indexed value and volume sales and average price, 2002-06
    • Figure 31: 5EU sales by leading antifungal brands versus rest of market by indexed value and volume sales and average price, 2002-06
    • Figure 32: 7MM antifungal sales by region: - indexed volume and value sales and average pricing, 2002-06
    • Figure 33: Forecast 7MM antifungal sales by volume, value and region, 2006-2016
    • Figure 34: Forecast new launches, existing products and generics by regional contribution, and CAGR (2006-16)
    • Figure 35: Forecast 7MM antifungals sales by region - new launch, existing product and generic contribution, 2006-2016
    • Figure 36: Key events impacting the azole class, s2002-2016
    • Figure 37: Events impacting Azole class members, 2007-2016
    • Figure 38: Indexed 7MM azole class sales versus rest of antifungal market sales , 2002-06
    • Figure 39: Forecast 7MM azole class sales versus rest of antifungal market, 2006-2016
    • Figure 40: Indexed 7MM azole sales by region, 2002-062002-06
    • Figure 41: Forecast 7MM azole class sales by region, 2006-16
    • Figure 42: Forecast 7MM azole sales - new launches, existing products and generics, 2006-2016
    • Figure 43: Indexed 7MM azole class sales - key brands and generics, 2002-06
    • Figure 44: Forecast 7MM azole class sales - key brands and generics, 2006-2016
    • Figure 45: Indexed 7MM generic azole volume and value sales, 2002-06
    • Figure 46: Forecast 7MM azole generic sales by molecule and combined brands, 2006-2016
    • Figure 47: Diflucan 7MM key metrics - indexed volume and value sales, and average pricing, 2002-06
    • Table 58: Prodif: Key facts
    • Figure 48: Prodif 7MM key metrics - indexed volume and value sales, and average pricing, 2002-06
    • Table 59: Sporanox: Key facts
    • Figure 49: Sporanox 7MM key metrics - indexed volume and value sales, and average pricing, 2002-06
    • Table 60: Nizoral: Key facts
    • Figure 50: Nizoral 7MM key metrics - indexed volume and value sales, and average pricing, 2002-06
    • Table 61: Noxafil: Key facts
    • Figure 51: Noxafil 7MM key metrics - indexed volume and value sales, and average pricing, 2002-06
    • Table 63: Vfend: Key facts
    • Figure 52: Vfend 7MM key metrics - indexed volume and value sales, and average pricing 2002-06
    • Table 64: Isavuconazonium chloride: Key facts
    • Table 65: UR-9825: Key facts
    • Table 66: E1224: Key facts
    • Table 67: Ravuconazole: Key facts
    • Table 68: SSY-726: Key facts
    • Figure 53: Key events impacting the echinocandin class events, 2001-2016
    • Figure 54: Events impacting echinocandin class members, 2007-2016
    • Figure 55: Indexed 7MM echinocandin sales versus rest of antifungal market sales, 2002-06
    • Figure 56: Forecast echinocandin sales versus rest of antifungal market 7MM by volume and value, 2006-2016
    • Figure 57: Forecast 7MM volume and value echinocandin sales -new launches, existing products and generics, 2006-2016
    • Figure 58: Total echinocandin sales by region, , 2002-06
    • Figure 59: Forecast 7MM echinocandin sales by region, 2006-2016
    • Figure 60: Key echinocandin brands and generics - indexed 7MM sales, 2002-06
    • Figure 61: Forecast 7MM echinocandin brand and combined generic sales, 2006-2016
    • Table 76: Cancidas: Key facts
    • Figure 62: Cancidas 7MM key metrics - indexed volume and value sales and average pricing, 2002-06
    • Figure 63: Indexed US branded echinocandin volume and value sales, 2002-06
    • Table 77: Mycamine: Key facts
    • Figure 64: Mycamine 7MM key metrics - indexed volume and value sales and average pricing, 2002-06
    • Figure 65: Indexed US echinocandin wholesale pricing tactics by quarter, Q2 2005-Q2 2007
    • Table 78: Eraxis: Key facts
    • Figure 66: Eraxis 7MM key metrics - indexed volume and value sales, and average pricing 2002-06
    • Figure 67: Indexed first five quarter volume and value sales, Mycamine versus Eraxis, Q2 2005-Q2 2006
    • Table 79: HMR-3270: Key facts
    • Figure 68: Key events impacting the polyene class, 2002-2014
    • Figure 69: Events impacting polyene class members, 2007-2016
    • Figure 70: Indexed 7MM polyene class sales versus rest of antifungal market, 2002-06
    • Figure 71: Forecast 7MM polyene sales versus rest of antifungal market: key metrics - volume and value sales and average pricing, 2006-2016
    • Figure 72: Indexed 7MM polyene class sales by region, 2002-06
    • Figure 73: Forecast 7MM volume and value polyene sales by region, 2006-2016
    • Figure 74: Forecast 7MM polyene sales - new launches, existing products and generics, 2006-2016
    • Figure 75: Indexed 7MM polyene class sales - key brands and generics, 2006-
    • Figure 76: Forecast 7MM volume and value polyene brand sales and combined generics, 2006-2016
    • Table 87: Abelcet: Key facts
    • Figure 77: Abelcet 7MM key metrics - indexed volume and value sales and average pricing 2002-06
    • Table 88: AmBisome: Key facts
    • Figure 78: AmBisome 7 Major Markets key metrics - indexed volume and value sales and average pricing 2002-06
    • Figure 79: AmBisome - indexed volume sales by region, 2002-06
    • Table 90: SinuNase & BiOral Amphotericin B - Amphotericin B Oral and Nasal cochleates: Key facts
    • Table 91: NKTR-024 - amphotericin B inhalation powder: Key facts
    • Figure 80: Forecast 7MM volume and value Others brand sales and combined generics, 2006-16
    • Table 97: Mycograb: Key facts